-
Lingke Pharmaceuticals Announces the Completion of the First Patient Dosing in the Phase II Clinical Study of LNK01001 in the Treatment of Atopic Dermatitis
Time of Update: 2022-05-01
The company recently announced that the first patient has been dosed in a Phase II clinical trial of its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases in atopic dermatitis (AD) .
-
Caring for "Liu Xuezhou" - Inventory of the pathogenesis of depression and related drugs
Time of Update: 2022-05-01
6 Comprehensive effects of multiple factors Statistical analysis of the serum test results of most patients with depression showed that the content of monoamine neurotransmitters decreased, and the expression levels of cytokines and NTF also changed accordingly.
7 SARI serotonin receptor antagonist/reuptake inhibitor: the representative drug is trazodone; it is a second-line antidepressant .
-
Talking about: Factors and Absorption Routes Affecting Oral Drug Absorption
Time of Update: 2022-05-01
During the absorption process, drug molecules pass through the lipid membrane from the gastrointestinal tract in the high concentration area by passive diffusion and enter the blood in the low concentration area .
-
First report!
Time of Update: 2022-05-01
4) Source: Minet China Drug Clinical Trials Publicity Library Since 2019, Renfu Medicine has applied for a total of 8 new improved drugs, among which isoflurane injection has applied for marketing and is under review, dexmedetomidine transdermal patch (II) has applied for clinical application and is under review, and Shufen/Tai/ The transdermal patch and dexmedetomidine transdermal patch are undergoing Phase I clinical trials, and the remaining 4 have also obtained clinical approvals .
-
Jinyao Pharmaceutical Metahydroxylamine Bitartrate Injection passed the consistency evaluation
Time of Update: 2022-04-30
On March 7, NMPA's official website showed that Tianjin Jinyao Pharmaceutical's metahydroxylamine bitartrate injection passed the consistency evaluation of generic drugs, which was the first domestic evaluation .
-
The New "Revolution" of Cell Therapy——Global R&D Overview of TCR-T Therapy
Time of Update: 2022-04-28
TCR-T technology has undergone four iterations in the development process: 01 The first generation of TCR-T is a subset of T cells that are specifically recognized by tumor antigens isolated from patient T cells, expanded in vitro and then reinfused for treatment .
-
Ascentage Pharma Completes First Patient Dosing in China's Key Registration Phase II Clinical Trial of Bcl-2 Selective Inhibitor APG-2575 for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Time of Update: 2022-04-26
Ascentage Pharma (6855. HK), a leading biopharmaceutical company dedicated to the development of innovative drugs in the therapeutic areas of oncology, hepatitis B and aging-related diseases, announc
-
Henlius ACE2-Fc receptor fusion protein HLX71 Phase I clinical results are positive
Time of Update: 2022-04-26
It is reported that HLX71 is a self-developed recombinant human Angiotensin converting enzyme 2 (hACE2) fusion protein with IgG1 Fc at the C-terminus, which is intended for the treatment of novel coronavirus pneumonia (COVID-19) .
-
Leuprolide injection emulsion, a subsidiary of Changchun Hi-Tech Holdings, was approved for clinical use
Time of Update: 2022-04-26
Changchun Hi-Tech announced that its holding subsidiary Jinsai Pharmaceuticals Leuprolide Injection Emulsion has recently received a drug clinical trial approval notice from NMPA . According to the
-
Genenforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Advanced Therapeutics Development
Time of Update: 2022-04-26
Chris Jeffers, Chief Executive Officer of Hibiscus BioTechnology, said, "This strategic partnership with Jianxin Forces underscores our commitment to growing Hibiscus Studio's pipeline, enhancing our operational capabilities, and advancing the development and commercialization of innovative medicines.
-
Sunshine Guojian SSGJ-613 Phase Ia study enrollment completed, the new indication for acute gouty arthritis has been approved by NMPA and Phase Ib/II clinical trials will be launched in the near future
Time of Update: 2022-04-26
Canakinumab is an indication for the treatment of acute gouty arthritis, but there is no self-developed monoclonal antibody against IL-1β on the market in China, and there is still a huge unmet clinical need in this therapeutic area .
-
Due to the clear positive effect shown in patients with chronic kidney disease, the EMPA-KIDNEY phase III clinical trial of Otani® (empagliflozin) will be terminated early
Time of Update: 2022-04-25
Following a formal interim review, the Independent Data Monitoring Committee recommends early termination of the EMPA-KIDNEY clinical trial EMPA-KIDNEY is the largest and most extensive clinical tria
-
CStone Pharmaceuticals Announces that the International Multicenter Registration Study of PD-1 Antibody Nofazinlimab Combined with Lenvatinib in First-Line Treatment of Advanced Hepatocellular Carcinoma Successfully Achieved the Predefined Patient Enrollment Target
Time of Update: 2022-04-25
CStone Pharmaceuticals (Hong Kong Stock Exchange: 2616) recently announced that its PD-1 antibody nofazinlimab (CS1003) combined with lenvatinib in the first-line treatment of patients with advanced hepatocellular carcinoma (HCC) is an international multicenter Phase III registrational study CS1003- 305 The pre-set patient enrollment target was successfully achieved .
-
Zai Lab Reports Positive Results of PRIME Phase 3 Clinical Study of Zele® (Niraparib) at the American Society of Gynecologic Oncology (SGO) Annual Meeting
Time of Update: 2022-04-25
Research confirms that Zele® is effective in newly diagnosed Chinese patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively referred to as ovarian cancer), regardless of biomarker status, following platinum-based chemotherapy Statistically and clinically significant improvement in progression-free survival (PFS) as maintenance therapy with a tolerable safety profile .
-
The performance soared 468 times!
Time of Update: 2022-04-25
Revenue increased 468 times, 5 new category 1 drugs on the way On March 14, Rongchang Bio disclosed a letter of intent for listing on the Science and Technology Innovation Board, and officially entered the issuance stage.
-
Highlights of adjuvant therapy for NSCLC: Phase III clinical data of T drug approved for adjuvant immune drug K drug released
Time of Update: 2022-04-24
), postoperative treatment with Keytruda reduced the risk of disease recurrence or death by 24% in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) compared with placebo .
3. https:// -approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer 4.
-
Treat Pruritus from Canine Allergic Dermatitis!
Time of Update: 2022-04-24
Yinming Bio announced that the original small-molecule drug GGW0014 under development by its subsidiary, Gwitch, has completed the clinical filing of a new class of veterinary drug on March 17, 2022.
-
Published data from Merck's pembrolizumab adjuvant treatment in patients with stage IB-IIIA non-small cell lung cancer (NSCLC)
Time of Update: 2022-04-23
. KEYNOTE-091 is a randomized, triple-blind, phase III trial evaluating pembrolizumab, versus placebo, with or without adjuvant chemotherapy as surgical resection (lobectomy or pneumonectomy) Differences in the efficacy and safety of adjuvant therapy in patients with post-IB-IIIA (AJCC 7th edition TNM staging criteria) non-small cell lung cancer .
-
The results of Phase II clinical trial of VVN001, an innovative drug for dry eye disease of Vimbi Biosciences in the United States, are positive
Time of Update: 2022-04-23
VivaVision, a clinical-stage biotechnology company focusing on ophthalmology, is pleased to announce that its self-developed innovative drug VVN001 has achieved positive results in the US Phase II clinical trial for dry eye disease .
-
Chengdu Bite two varieties of oseltamivir were approved on the same day
Time of Update: 2022-04-22
0 China Drug Evaluation Database In addition, more than 10 companies including Anhui Pioneer Pharmaceutical, Yangzijiang Pharmaceutical Group, and Chongqing Shenghuaxi Pharmaceutical have submitted their listing applications for Oseltamivir Phosphate Capsules under review and approval .
